Payment overview · 2025
General Payments
$110,986.58
107 reported records · 22 companies
Healthcare provider profile · identity verified
Risal S Djohan, MD
Allopathic & Osteopathic Physicians|Plastic Surgery · CLEVELAND, OH · NPI 1477517183
Verified facts
What the public records show
CMS Open Payments records show Risal S Djohan, MD received $110,986.58 in general payments during 2025 across 107 reported records.
Solventum Corporation accounted for 41.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 50 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Solventum Corporation | Unresolved — no canonical attribution shown | $45,795.70 | 41.3% | 25 | 2025 |
| AXOGEN | Unresolved — no canonical attribution shown | $29,075.26 | 26.2% | 23 | 2025 |
| Pacira Pharmaceuticals Incorporated | Unresolved — no canonical attribution shown | $17,020.00 | 15.3% | 1 | 2025 |
| Mentor Worldwide LLC | Unresolved — no canonical attribution shown | $8,840.53 | 8.0% | 14 | 2025 |
| Integra LifeSciences Corporation | Unresolved — no canonical attribution shown | $4,192.86 | 3.8% | 7 | 2025 |
| RTI SURGICAL, INC | Unresolved — no canonical attribution shown | $1,937.58 | 1.8% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $1,491.76 | 1.3% | 9 | 2025 |
| Musculoskeletal Transplant Foundation Inc. | Unresolved — no canonical attribution shown | $722.74 | 0.7% | 4 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $502.67 | 0.5% | 3 | 2025 |
| Acera Surgical, Inc. | Unresolved — no canonical attribution shown | $238.60 | 0.2% | 2 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $203.50 | 0.2% | 2 | 2025 |
| PolyNovo North America LLC | Unresolved — no canonical attribution shown | $150.84 | 0.1% | 1 | 2025 |
| Dilon Technologies, Inc. | Unresolved — no canonical attribution shown | $148.08 | 0.1% | 1 | 2025 |
| Aroa Biosurgery Incorporated | Unresolved — no canonical attribution shown | $139.50 | 0.1% | 1 | 2025 |
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $121.83 | 0.1% | 1 | 2025 |
| MOTIVA USA, LLC | Unresolved — no canonical attribution shown | $101.92 | 0.1% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $95.97 | 0.1% | 1 | 2025 |
| Endomagnetics Ltd | Unresolved — no canonical attribution shown | $82.09 | 0.1% | 2 | 2025 |
| Ethicon Inc. | Unresolved — no canonical attribution shown | $42.85 | 0.0% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $30.54 | 0.0% | 1 | 2025 |
| Ethicon US, LLC | Unresolved — no canonical attribution shown | $26.23 | 0.0% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$25.53 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $74,395.00 | 13 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $20,800.00 | 2 |
| Food and Beverage | $6,789.20 | 76 |
| Travel and Lodging | $5,173.63 | 14 |
| Long term medical supply or device loan | $2,328.75 | 1 |
| Honoraria | $1,500.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| V.A.C.ULTA Normalized: v a c ulta |
Device | Solventum Corporation | $34,018.05 | 6 | 2025 |
Source payment records
|
|||||
| PREVENA Normalized: prevena |
Device | Solventum Corporation | $30,689.54 | 15 | 2025 |
Source payment records
|
|||||
| V.A.C. VERAFLO Normalized: v a c veraflo |
Device | Solventum Corporation | $29,727.40 | 5 | 2025 |
Source payment records
|
|||||
| AXOGUARD Normalized: axoguard |
Device | AXOGEN | $28,771.26 | 17 | 2025 |
Source payment records
|
|||||
| AXOGUARD HA+ NERVE PROTECTOR Normalized: axoguard ha nerve protector |
Device | AXOGEN | $28,771.26 | 17 | 2025 |
Source payment records
|
|||||
| AXOGUARD NERVE CAP Normalized: axoguard nerve cap |
Device | AXOGEN | $28,771.26 | 17 | 2025 |
Source payment records
|
|||||
| PREVENA RESTOR BELLAFORM Normalized: prevena restor bellaform |
Device | Solventum Corporation | $20,922.17 | 3 | 2025 |
Source payment records
|
|||||
| PROMOGRAN PRISMA Normalized: promogran prisma |
Device | Solventum Corporation | $20,922.17 | 3 | 2025 |
Source payment records
|
|||||
| Exparel Normalized: exparel |
Drug | Pacira Pharmaceuticals Incorporated | $17,020.00 | 1 | 2025 |
Source payment records
|
|||||
| Iovera Normalized: iovera |
Device | Pacira Pharmaceuticals Incorporated | $17,020.00 | 1 | 2025 |
Source payment records
|
|||||
| Zilretta Normalized: zilretta |
Drug | Pacira Pharmaceuticals Incorporated | $17,020.00 | 1 | 2025 |
Source payment records
|
|||||
| 3M Micropore Normalized: 3m micropore |
Device | Solventum Corporation | $13,161.07 | 4 | 2025 |
Source payment records
|
|||||
| ATTEST Normalized: attest |
Device | Solventum Corporation | $13,161.07 | 4 | 2025 |
Source payment records
|
|||||
| Bair Hugger Normalized: bair hugger |
Device | Solventum Corporation | $13,161.07 | 4 | 2025 |
Source payment records
|
|||||
| Curos Normalized: curos |
Device | Solventum Corporation | $13,161.07 | 4 | 2025 |
Source payment records
|
|||||
| V.A.C. GRANUFOAM Normalized: v a c granufoam |
Device | Solventum Corporation | $8,000.00 | 1 | 2025 |
Source payment records
|
|||||
| DuraSorb Monofilament Mesh Normalized: durasorb monofilament mesh |
Device | Integra LifeSciences Corporation | $2,328.75 | 1 | 2025 |
Source payment records
|
|||||
| CORTIVA ALLOGRAFT DERMIS Normalized: cortiva allograft dermis |
Device | RTI SURGICAL, INC | $1,937.58 | 5 | 2025 |
Source payment records
|
|||||
| SURGIMEND Normalized: surgimend |
Device | Integra LifeSciences Corporation | $1,864.11 | 6 | 2025 |
Source payment records
|
|||||
| V.A.C. VERAFLO CLEANSE CHOICE Normalized: v a c veraflo cleanse choice |
Device | Solventum Corporation | $1,820.50 | 4 | 2025 |
Source payment records
|
|||||
| CODMAN CERTAS Normalized: codman certas |
Device | Integra LifeSciences Corporation | $1,684.98 | 3 | 2025 |
Source payment records
|
|||||
| ABTHERA Normalized: abthera |
Device | Solventum Corporation | $800.00 | 1 | 2025 |
Source payment records
|
|||||
| NATRELLE SALINE-FILLED BREAST IMPLANTS Normalized: natrelle saline filled breast implants |
Device | ABBVIE INC. | $492.80 | 6 | 2025 |
Source payment records
|
|||||
| GORE ENFORM Preperitoneal Biomaterial Normalized: gore enform preperitoneal biomaterial |
Device | W. L. Gore & Associates, Inc. | $344.04 | 2 | 2025 |
Source payment records
|
|||||
| MENTOR MemoryGel Resterilizable Gel Sizer Normalized: mentor memorygel resterilizable gel sizer |
Device | Mentor Worldwide LLC | $343.58 | 10 | 2025 |
Source payment records
|
|||||
| Restrata Wound Matrix Normalized: restrata wound matrix |
Device | Acera Surgical, Inc. | $238.60 | 2 | 2025 |
Source payment records
|
|||||
| V.A.C.INSTILL Normalized: v a c instill |
Device | Solventum Corporation | $207.10 | 3 | 2025 |
Source payment records
|
|||||
| NEURAGEN Normalized: neuragen |
Device | Integra LifeSciences Corporation | $184.98 | 2 | 2025 |
Source payment records
|
|||||
| PRIMATRIX Normalized: primatrix |
Device | Integra LifeSciences Corporation | $184.98 | 2 | 2025 |
Source payment records
|
|||||
| Integra Normalized: integra |
Device | Integra LifeSciences Corporation | $179.13 | 3 | 2025 |
Source payment records
|
|||||
| Integra Dermal Regeneration Template Normalized: integra dermal regeneration template |
Device | Integra LifeSciences Corporation | $179.13 | 3 | 2025 |
Source payment records
|
|||||
| OMNIGRAFT Normalized: omnigraft |
Device | Integra LifeSciences Corporation | $179.13 | 3 | 2025 |
Source payment records
|
|||||
| Product in Development Normalized: product in development |
Device | W. L. Gore & Associates, Inc. | $158.63 | 1 | 2025 |
Source payment records
|
|||||
| AFFINITY Normalized: affinity |
Medical Supply | Organogenesis Inc. | $153.83 | 1 | 2025 |
Source payment records
|
|||||
| NOVOSORB BTM Normalized: novosorb btm |
Device | PolyNovo North America LLC | $150.84 | 1 | 2025 |
Source payment records
|
|||||
| HEMOBLAST BELLOWS Normalized: hemoblast bellows |
Device | Dilon Technologies, Inc. | $148.08 | 1 | 2025 |
Source payment records
|
|||||
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $121.83 | 1 | 2025 |
Source payment records
|
|||||
| Magtrace Normalized: magtrace |
Device | Endomagnetics Ltd, Hologic Sales and Service, LLC | $112.63 | 3 | 2025 |
Source payment records
|
|||||
| Motiva Implant Matrix Normalized: motiva implant matrix |
Device | MOTIVA USA, LLC | $101.92 | 1 | 2025 |
Source payment records
|
|||||
| ARTOURA Breast Tissue Expander Normalized: artoura breast tissue expander |
Device | Mentor Worldwide LLC | $96.95 | 1 | 2025 |
Source payment records
|
|||||
| MOLLI Normalized: molli |
Device | Stryker Corporation | $95.97 | 1 | 2025 |
Source payment records
|
|||||
| SPY-PHI SYSTEM Normalized: spy phi system |
Device | Stryker Corporation | $95.97 | 1 | 2025 |
Source payment records
|
|||||
| Magseed Normalized: magseed |
Device | Endomagnetics Ltd | $82.09 | 2 | 2025 |
Source payment records
|
|||||
| Sentimag Normalized: sentimag |
Device | Endomagnetics Ltd | $82.09 | 2 | 2025 |
Source payment records
|
|||||
| PURAFORCE Normalized: puraforce |
Device | Organogenesis Inc. | $49.67 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $26.48 | 1 | 2025 |
Source payment records
|
|||||
| ETHICON Normalized: ethicon |
Device | Ethicon US, LLC | $26.23 | 1 | 2025 |
Source payment records
|
|||||
| STRATAFIX Normalized: stratafix |
Device | Ethicon US, LLC | $26.23 | 1 | 2025 |
Source payment records
|
|||||
| AUTO SUTURE Normalized: auto suture |
Device | Medtronic, Inc. | $25.53 | 1 | 2025 |
Source payment records
|
|||||
| ACTIV.A.C. Normalized: activ a c |
Device | Solventum Corporation | $16.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $110,986.58 · 107 records | Solventum Corporation | 3M Micropore, ABTHERA, ACTIV.A.C., AFFINITY, ARTOURA Breast Tissue Expander, ATTEST, AUTO SUTURE, AXOGUARD, AXOGUARD HA+ NERVE PROTECTOR, AXOGUARD NERVE CAP, BOTOX, Bair Hugger, CODMAN CERTAS, CORTIVA ALLOGRAFT DERMIS, Curos, Da Vinci Surgical System, DuraSorb Monofilament Mesh, ETHICON, Exparel, GORE ENFORM Preperitoneal Biomaterial, HEMOBLAST BELLOWS, Integra, Integra Dermal Regeneration Template, Iovera, MENTOR MemoryGel Resterilizable Gel Sizer, MOLLI, Magseed, Magtrace, Motiva Implant Matrix, NATRELLE SALINE-FILLED BREAST IMPLANTS, NEURAGEN, NOVOSORB BTM, OMNIGRAFT, PREVENA, PREVENA RESTOR BELLAFORM, PRIMATRIX, PROMOGRAN PRISMA, PURAFORCE, Product in Development, Restrata Wound Matrix, SPY-PHI SYSTEM, STRATAFIX, SURGIMEND, Sentimag, V.A.C. GRANUFOAM, V.A.C. VERAFLO, V.A.C. VERAFLO CLEANSE CHOICE, V.A.C.INSTILL, V.A.C.ULTA, Zilretta | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error